Srivani Ravoori, PhD

Srivani Ravoori, PhD, is associate director of science communications at the AACR. Ravoori is an experienced science content developer and an expert in translating complex cancer science into simple language with the goal of educating the public, media, policymakers, and the health care industry about the importance of cancer research. She guides the Communications and Public Relations department in identifying the latest cancer research advances and disseminate them through various print and social media platforms. She holds a PhD degree in cancer biology and dedicated the first 15 years of her career to conducting basic and translational cancer research.

Toward Achieving Health Equity – A Preview of the 12th AACR Cancer Health Disparities Conference

In recent decades, the cancer research community has made great strides by bringing new, targeted, safer, and longer-lasting treatments to patients dealing with a variety of cancers. While this achievement is truly remarkable and laudable, a glaring fact is that these groundbreaking advances have not translated into progress for everyone.

Read More

AACR Annual Meeting 2019: Leaders Share Highlights and Future Direction

One of the world’s largest cancer research conferences, the AACR Annual Meeting 2019, came to an end with a plenary session titled “AACR Annual Meeting 2019 Highlights: Vision for the Future.” Leaders of the AACR provided an overview of the stellar presentations from the meeting on the topics of prevention, early detection, interception, and the latest breakthroughs in cutting-edge basic, translational, and clinical research.

Read More

AACR Annual Meeting 2019: New Approaches to Treating Drug-resistant Non-small Cell Lung Cancer

About 80 percent of lung cancers are non-small cell lung cancers (NSCLC), and about 15 to 20 percent of NSCLCs harbor epidermal growth factor receptor (EGFR)-activating mutations.
Treatment for EGFR-mutant NSCLC improved dramatically with the introduction of EGFR tyrosine kinase inhibitors (TKIs). Several TKIs targeting this receptor have been developed, including the U.S. Food and Drug Administration (FDA)-approved first-generation EGFR TKIs gefitinib (Iressa) and erlotinib (Tarceva); second-generation EGFR TKIs, such as the FDA-approved afatinib (Gilotrif) and dacomitinib (Vizimpro), and the investigational therapeutic neratinib; and third-generation EGFR TKIs, including the FDA-approved osimertinib (Tagrisso), and the investigational therapeutics olmutinib and nazartinib.

Read More

AACR Annual Meeting 2019: Optimizing PD-1/PD-L1 Immune Checkpoint Inhibitor Therapy

Immune checkpoint inhibitors have become part of the standard of care for more than 14 different cancer types, including melanoma, lung cancer, head and neck cancer, bladder cancer, cervical cancer, liver cancer, stomach cancer, breast cancer, lymphoma, and to treat patients with any type of solid tumor that is microsatellite instability–high or mismatch repair–deficient. In a clinical trial plenary session held April 1 at the AACR Annual Meeting 2019, titled “Optimizing PD-1/PD-L1 Immune Checkpoint Inhibitor Therapy: Dedicated to the Memory of Waun Ki Hong,” cancer researchers updated attendees on the latest advances in the utility of this class of immunotherapeutics, either as monotherapy or in combination with other treatment modalities.

Read More

AACR Annual Meeting 2019: Promising Data from CAR T-cell Clinical Trials for Advanced Solid Tumors

A pair of studies presented at the AACR Annual Meeting 2019 demonstrated encouraging clinical outcomes with two different chimeric antigen receptor (CAR) T-cell therapies for patients with advanced solid tumors.

CAR T-cell therapy is a type of immunotherapy in which T cells are removed from a patient’s body and genetically modified so that they can recognize the patient’s cancer cells. The modified T cells, when reintroduced into the patient’s body, multiply and attack cancer cells. The U.S. Food and Drug Administration has approved two CAR T-cell therapies for blood cancers so far: tisagenlecleucel (Kymriah) for treating certain patients with acute lymphoblastic leukemia or non-Hodgkin lymphoma (NHL), and axicabtagene ciloleucel (Yescarta) for treating certain adults with NHL.

Read More

AACR Annual Meeting 2019 Opening Plenary Session: Wearable Technologies, Precision Medicine, and Immunotherapy

The spectacular sight of the AACR Annual Meeting 2019 Opening Ceremony, held Sunday, March 31, at the Georgia World Congress Center in Atlanta was immediately followed by a splendid opening plenary session, titled “Achieving Equitable Patient Care through Precision and Convergent Cancer Science.”

Read More

Experts Forecast Cancer Research and Treatment Advances in 2019

In 2018, we witnessed significant momentum in several hot areas of cancer research, including immunotherapy and precision medicine. Researchers have amassed exponential amounts of knowledge in these areas of scientific inquiry in recent years, and 2018 saw many of these gains culminate into innovative treatments for cancer patients.

Read More

Research Highlights from the San Antonio Breast Cancer Symposium 2018

The 41st San Antonio Breast Cancer Symposium, held Dec. 4-8, drew more than 7,500 attendees from more than 90 countries. The Symposium offered the latest clinical, translational, and basic research, providing a forum for interaction and communication among researchers, health professionals, and those with a special interest in breast cancer.

Read More